Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants

Sing Mei Lim; Hoi Lok Cheng; Huan Jia; Patthara Kongsuphol; Bhuvaneshwari D/O Shunmuganathan; Ming Wei Chen; Say Yong Ng; Xiaohong Gao; Shuvan Prashant Turaga; Sascha P. Heussler; Jyoti Somani; Sharmila Sengupta; Dousabel M.Y. Tay; Megan E. McBee; Barnaby E. Young; Paul A. MacAry; Hadley D. Sikes; Peter R. Preiser

doi:10.1002/btm2.10293

Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants

Sing Mei Lim, Hoi Lok Cheng, Huan Jia, Patthara Kongsuphol, Bhuvaneshwari D/O Shunmuganathan, Ming Wei Chen, Say Yong Ng, Xiaohong Gao, Shuvan Prashant Turaga, Sascha P. Heussler, Jyoti Somani, Sharmila Sengupta, Dousabel M.Y. Tay, Megan E. McBee, Barnaby E. Young, Paul A. MacAry, Hadley D. Sikes^*, Peter R. Preiser^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic's changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type (WT), alpha, beta, gamma, and delta variant RBDs. It captures a clinically relevant range of nAb levels, and effectively differentiates prevaccination, post first dose, and post second dose vaccination samples within 10 min. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a postvaccinated population.

Original language	English
Article number	e10293
Journal	Bioengineering and Translational Medicine
Volume	7
Issue number	2
DOIs	https://doi.org/10.1002/btm2.10293
Publication status	Published - May 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.

ASJC Scopus Subject Areas

Biotechnology
Biomedical Engineering
Pharmaceutical Science

Keywords

cellulose pulldown assay
COVID19
humoral response against COVID19 variants
neutralizing antibody
point-of-care test
SARS-CoV-2
serology test

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/btm2.10293

Cite this

Lim, S. M., Cheng, H. L., Jia, H., Kongsuphol, P., D/O Shunmuganathan, B., Chen, M. W., Ng, S. Y., Gao, X., Turaga, S. P., Heussler, S. P., Somani, J., Sengupta, S., Tay, D. M. Y., McBee, M. E., Young, B. E., MacAry, P. A., Sikes, H. D., & Preiser, P. R. (2022). Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants. Bioengineering and Translational Medicine, 7(2), Article e10293. https://doi.org/10.1002/btm2.10293

@article{bedf011652fa4336950265d5c53f743d,

title = "Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants",

abstract = "There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic's changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type (WT), alpha, beta, gamma, and delta variant RBDs. It captures a clinically relevant range of nAb levels, and effectively differentiates prevaccination, post first dose, and post second dose vaccination samples within 10 min. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a postvaccinated population.",

keywords = "cellulose pulldown assay, COVID19, humoral response against COVID19 variants, neutralizing antibody, point-of-care test, SARS-CoV-2, serology test",

author = "Lim, {Sing Mei} and Cheng, {Hoi Lok} and Huan Jia and Patthara Kongsuphol and {D/O Shunmuganathan}, Bhuvaneshwari and Chen, {Ming Wei} and Ng, {Say Yong} and Xiaohong Gao and Turaga, {Shuvan Prashant} and Heussler, {Sascha P.} and Jyoti Somani and Sharmila Sengupta and Tay, {Dousabel M.Y.} and McBee, {Megan E.} and Young, {Barnaby E.} and MacAry, {Paul A.} and Sikes, {Hadley D.} and Preiser, {Peter R.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.",

year = "2022",

month = may,

doi = "10.1002/btm2.10293",

language = "English",

volume = "7",

journal = "Bioengineering and Translational Medicine",

issn = "2380-6761",

publisher = "John Wiley & Sons Inc.",

number = "2",

}

Lim, SM, Cheng, HL, Jia, H, Kongsuphol, P, D/O Shunmuganathan, B, Chen, MW, Ng, SY, Gao, X, Turaga, SP, Heussler, SP, Somani, J, Sengupta, S, Tay, DMY, McBee, ME, Young, BE, MacAry, PA, Sikes, HD & Preiser, PR 2022, 'Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants', Bioengineering and Translational Medicine, vol. 7, no. 2, e10293. https://doi.org/10.1002/btm2.10293

TY - JOUR

T1 - Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants

AU - Lim, Sing Mei

AU - Cheng, Hoi Lok

AU - Jia, Huan

AU - Kongsuphol, Patthara

AU - D/O Shunmuganathan, Bhuvaneshwari

AU - Chen, Ming Wei

AU - Ng, Say Yong

AU - Gao, Xiaohong

AU - Turaga, Shuvan Prashant

AU - Heussler, Sascha P.

AU - Somani, Jyoti

AU - Sengupta, Sharmila

AU - Tay, Dousabel M.Y.

AU - McBee, Megan E.

AU - Young, Barnaby E.

AU - MacAry, Paul A.

AU - Sikes, Hadley D.

AU - Preiser, Peter R.

PY - 2022/5

Y1 - 2022/5

N2 - There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic's changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type (WT), alpha, beta, gamma, and delta variant RBDs. It captures a clinically relevant range of nAb levels, and effectively differentiates prevaccination, post first dose, and post second dose vaccination samples within 10 min. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a postvaccinated population.

AB - There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemic's changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type (WT), alpha, beta, gamma, and delta variant RBDs. It captures a clinically relevant range of nAb levels, and effectively differentiates prevaccination, post first dose, and post second dose vaccination samples within 10 min. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a postvaccinated population.

KW - cellulose pulldown assay

KW - COVID19

KW - humoral response against COVID19 variants

KW - neutralizing antibody

KW - point-of-care test

KW - SARS-CoV-2

KW - serology test

UR - http://www.scopus.com/inward/record.url?scp=85124629370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124629370&partnerID=8YFLogxK

U2 - 10.1002/btm2.10293

DO - 10.1002/btm2.10293

M3 - Article

AN - SCOPUS:85124629370

SN - 2380-6761

VL - 7

JO - Bioengineering and Translational Medicine

JF - Bioengineering and Translational Medicine

IS - 2

M1 - e10293

ER -

Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

SMART and NTU Singapore develop a quick test kit to determine a person’s immunity against COVID-19 and its variants

Cite this

Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Press/Media

SMART and NTU Singapore develop a quick test kit to determine a person’s immunity against COVID-19 and its variants

Cite this